BR0302017A - Composição farmacêutica a base de um agonista do receptor central de benzodiazepìnicos - Google Patents

Composição farmacêutica a base de um agonista do receptor central de benzodiazepìnicos

Info

Publication number
BR0302017A
BR0302017A BR0302017-7A BR0302017A BR0302017A BR 0302017 A BR0302017 A BR 0302017A BR 0302017 A BR0302017 A BR 0302017A BR 0302017 A BR0302017 A BR 0302017A
Authority
BR
Brazil
Prior art keywords
weight
pharmaceutical composition
receptor agonist
composition based
benzodiazepine receptor
Prior art date
Application number
BR0302017-7A
Other languages
English (en)
Other versions
BR0302017B1 (pt
Inventor
Carlos Oliani
Adriano P Coelho
Heny C Zaniboni
Guido Vandoni
Original Assignee
Sigma Pharma Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Pharma Ltda filed Critical Sigma Pharma Ltda
Priority to BRPI0302017-7A priority Critical patent/BR0302017B1/pt
Priority to MXPA05013091A priority patent/MXPA05013091A/es
Priority to EP04734794A priority patent/EP1633366B1/en
Priority to RU2005136684/15A priority patent/RU2335288C2/ru
Priority to ES04734794T priority patent/ES2345984T3/es
Priority to DE602004026299T priority patent/DE602004026299D1/de
Priority to PCT/BR2004/000076 priority patent/WO2004105767A1/en
Priority to US10/559,290 priority patent/US8168625B2/en
Priority to AT04734794T priority patent/ATE462436T1/de
Publication of BR0302017A publication Critical patent/BR0302017A/pt
Publication of BR0302017B1 publication Critical patent/BR0302017B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA A BASE DE UM AGONISTA DO RECEPTOR CENTRAL DE BENZODIAZEPìNICOS". A presente invenção descreve o uso de compostos farmacêuticos em composições farmacêuticas para administração sublingual incluindo, como princípio ativo dos mesmos, um agonista do receptor central dos benzodiazepínicos escolhido entre diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam e maleato de midazolam em mistura com um excipiente farmacêutico composto por, pelo menos, 70% do peso da formulação final contendo 40 - 45% em peso de lactose, 15 - 27% em peso de sorbitol e 12 - 16% em peso de celulose.
BRPI0302017-7A 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos BR0302017B1 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
MXPA05013091A MXPA05013091A (es) 2003-06-02 2004-05-26 Composicion farmaceutica basada en agonistas de benzodiazepina.
EP04734794A EP1633366B1 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
RU2005136684/15A RU2335288C2 (ru) 2003-06-02 2004-05-26 Фармацевтическая композиция на основе агониста бензодиазепина
ES04734794T ES2345984T3 (es) 2003-06-02 2004-05-26 Composicion farmaceutica basada en agonista de la benzodiacepina.
DE602004026299T DE602004026299D1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis eines benzodiazepin-agonisten
PCT/BR2004/000076 WO2004105767A1 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
US10/559,290 US8168625B2 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on agonist of benzodiazepine
AT04734794T ATE462436T1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis eines benzodiazepin-agonisten

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos

Publications (2)

Publication Number Publication Date
BR0302017A true BR0302017A (pt) 2005-06-28
BR0302017B1 BR0302017B1 (pt) 2014-10-29

Family

ID=36596112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0302017-7A BR0302017B1 (pt) 2003-06-02 2003-06-02 Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos

Country Status (9)

Country Link
US (1) US8168625B2 (pt)
EP (1) EP1633366B1 (pt)
AT (1) ATE462436T1 (pt)
BR (1) BR0302017B1 (pt)
DE (1) DE602004026299D1 (pt)
ES (1) ES2345984T3 (pt)
MX (1) MXPA05013091A (pt)
RU (1) RU2335288C2 (pt)
WO (1) WO2004105767A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
EP2604257B1 (en) * 2007-08-07 2017-06-28 Acelrx Pharmaceuticals, Inc. Oral transmucosal dosage forms comprising sufentanil and triazolam
EP2087893B1 (en) * 2008-02-05 2013-02-13 Laboratorios Bagó S.A. Compositions comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and processes for preparing them
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
AU2014205356A1 (en) * 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
WO2017192921A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Enhanced delivery epinephrine compositions
EP3687509A1 (en) * 2017-09-27 2020-08-05 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof

Also Published As

Publication number Publication date
DE602004026299D1 (de) 2010-05-12
EP1633366A4 (en) 2008-02-27
RU2335288C2 (ru) 2008-10-10
US20060134200A1 (en) 2006-06-22
MXPA05013091A (es) 2006-03-09
ES2345984T3 (es) 2010-10-07
BR0302017B1 (pt) 2014-10-29
RU2005136684A (ru) 2007-07-20
EP1633366B1 (en) 2010-03-31
ATE462436T1 (de) 2010-04-15
EP1633366A1 (en) 2006-03-15
US8168625B2 (en) 2012-05-01
WO2004105767A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
BR0302017A (pt) Composição farmacêutica a base de um agonista do receptor central de benzodiazepìnicos
DE60132017D1 (de) Neue benzazepine und ähnliche heterocyclische derivate,die als orexin rezeptor antagonisten geeignet sind
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
DE60335891D1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
MY129150A (en) Novel sulfamides
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
IL154057A0 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
CA2402431A1 (en) 1,2,3,4-tetrahydroisoquinoline derivatives
SV2002000205A (es) Compuestos farmaceuticos ref. x-01095
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
WO2005032464A3 (en) Phenyl pyrrolidine ether tachykinin receptor antagonists
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
BR9909486A (pt) Compostos calcilìticos
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas
MY140724A (en) Novel arylethene-sulfonamides
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
UA86371C2 (ru) Фармацевтическая композиция на основе агониста бензодиазепина
BRPI0409957A (pt) imidazolin-2-ilaminofenil amidas
EP1879027A4 (en) AGENT FOR THE PREVENTION AND TREATMENT OF PANCREATITES

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: EMS SIGMA PHARMA LTDA (BR/SP)

B25G Requested change of headquarter approved

Owner name: EMS SIGMA PHARMA LTDA (BR/SP)

Free format text: SEDE ALTERADA CONFORME PETICAO NO 20130095866, DE 27/12/2013.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.